Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.
作者信息
Sekeres Mikkael A, Watts Justin, Radinoff Atanas, Sangerman Montserrat Arnan, Cerrano Marco, Lopez Patricia Font, Zeidner Joshua F, Campelo Maria Diez, Graux Carlos, Liesveld Jane, Selleslag Dominik, Tzvetkov Nikolay, Fram Robert J, Zhao Dan, Bell Jill, Friedlander Sharon, Faller Douglas V, Adès Lionel
机构信息
Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
University Hospital Sveti Ivan Rislki, Sofia, Bulgaria.
出版信息
Leukemia. 2021 Jul;35(7):2119-2124. doi: 10.1038/s41375-021-01125-4. Epub 2021 Jan 22.
Abstract
摘要
相似文献
1
Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.
Leukemia. 2021 Jul;35(7):2119-2124. doi: 10.1038/s41375-021-01125-4. Epub 2021 Jan 22.
2
Asia-inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial.
Clin Transl Sci. 2021 May;14(3):1069-1081. doi: 10.1111/cts.12972. Epub 2021 Feb 2.
3
Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.
Pathol Oncol Res. 2019 Jul;25(3):1175-1180. doi: 10.1007/s12253-018-00574-0. Epub 2019 Jan 6.
4
Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
Br J Haematol. 2011 Dec;155(5):599-606. doi: 10.1111/j.1365-2141.2011.08893.x. Epub 2011 Oct 8.
5
Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
Health Technol Assess. 2010 May;14 Suppl 1:69-74. doi: 10.3310/hta14Suppl1/10.
6
Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey.
Acta Clin Belg. 2015 Feb;70(1):34-43. doi: 10.1179/2295333714Y.0000000102. Epub 2014 Dec 2.
7
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.
J Hematol Oncol. 2023 Jul 8;16(1):73. doi: 10.1186/s13045-023-01476-8.
8
Azacitidine access program for Belgian patients with myelodysplastic syndromes, acute myeloid leukemia or chronic myelomonocytic leukemia.
Curr Med Res Opin. 2015 Jan;31(1):35-42. doi: 10.1185/03007995.2014.972499. Epub 2014 Oct 17.
9
Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies.
Am J Hematol. 2018 Oct;93(10):1199-1206. doi: 10.1002/ajh.25216. Epub 2018 Sep 3.
10
Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).
Int J Hematol. 2024 Feb;119(2):130-145. doi: 10.1007/s12185-023-03686-9. Epub 2023 Dec 13.
引用本文的文献
1
Novel small-molecule therapies for myelodysplastic syndromes with IPSS-R ⩾3.5 in patients aged 60 or older: current landscape and challenges.
Ther Adv Hematol. 2025 Sep 3;16:20406207251371298. doi: 10.1177/20406207251371298. eCollection 2025.
2
Advances and Challenges in the Management of Myelodysplastic Syndromes.
Cancers (Basel). 2025 Jul 25;17(15):2469. doi: 10.3390/cancers17152469.
3
Beyond Hypomethylating Agents: Novel Therapies and Targeted Approaches.
Clin Hematol Int. 2025 Aug 7;7(3):24-35. doi: 10.46989/001c.142956. eCollection 2025.
4
Glutamine Metabolism: Molecular Regulation, Biological Functions, and Diseases.
MedComm (2020). 2025 Jun 25;6(7):e70120. doi: 10.1002/mco2.70120. eCollection 2025 Jul.
5
Therapeutic targeting of the NOTCH1 and neddylation pathways in T cell acute lymphoblastic leukemia.
Proc Natl Acad Sci U S A. 2025 Apr 8;122(14):e2426742122. doi: 10.1073/pnas.2426742122. Epub 2025 Mar 31.
6
Unveiling Myelodysplastic Syndromes: Exploring Pathogenic Mechanisms and Therapeutic Advances.
Cancers (Basel). 2025 Feb 3;17(3):508. doi: 10.3390/cancers17030508.
7
Epigenetics-targeted drugs: current paradigms and future challenges.
Signal Transduct Target Ther. 2024 Nov 26;9(1):332. doi: 10.1038/s41392-024-02039-0.
8
Chronic myelomonocytic leukemia: molecular pathogenesis and therapeutic innovations.
Haematologica. 2025 Jan 1;110(1):22-36. doi: 10.3324/haematol.2024.286061.
9
Infections and antimicrobial prophylaxis in patients with myelodysplastic syndromes.
Semin Hematol. 2024 Dec;61(6):348-357. doi: 10.1053/j.seminhematol.2024.07.004. Epub 2024 Aug 3.
10
Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches.
Mol Cancer. 2024 Jul 25;23(1):148. doi: 10.1186/s12943-024-02046-3.
Zotero 插件